Glomerular Disease

Nephrology Careers: A Closer Look

Match season is upon us. Take a look at the variety of careers in nephrology, and ASN's Match resources.

North Carolina Medical Society Takes the Lead Supporting Physician Health

Physicians are highly dedicated professionals performing highly stressful jobs. In this Q&A, NCMS Executive Vice President and CEO Robert W. Seligson discusses recently launched efforts to proactively address stress, burnout and suicide risk in physicians. "We are offering the NCMS as an organization willing to take on this issue."

Interoperability and Health Data: Do We Need to Change the Definition?

This perspective piece argues "the MACRA definition of interoperability is based on an aging IEEE statement from 1990 and that definition was never intended to describe the interoperability of health data records nor interoperation of EHR or HIT systems.”​

ASN President's Column July 2016

In this month's column, ASN President Raymond C. Harris, MD, FASN discusses initiatives that are changing the practice landscape in nephrology.

Perspective: Why Nephrology Needs a Blockbuster Therapeutic

This insightful piece by  Dr. Bruce A. Molitoris proved to be the second most popular perspective KN Online posted in 2016.

Building the Nephrology Workforce

Building the Nephrology Workforce:  ASN Creates Workforce and Career Advancement Department

ASN Names Next Editor-in-Chief of CJASN

ASN has named Rajnish Mehrotra, MD, FASN, as CJASN Editor-in-Chief effective January 1, 2017. He will serve a six-year term.

Communities at ASN

ASN Communities offer multiple opportunities to connect with colleagues working in the areas that interest you most. Check out this rapidly growing and dynamic ASN initiative here.

New Insights into Role of APOL1 Gene Variants and FSGS

Among 94 patients with focal segmental glomerulosclerosis (FSGS), those with 2 APOL1 variants tended to have more advanced disease at diagnosis, which fits with observations that this genetic form of FSGS progresses rapidly. Patients with the variants responded to cyclosporine and mycophenolate mofetil just as well as other patients, but they progressed more rapidly to kidney failure.

Pages